Univest
Univest
  • Markets

Fortis Healthcare vs Max Healthcare Institute 2027: The Market Pays 71x for One Hospital Chain and 57x for the Other

  • November 17, 2026
  • Posted by: Neeraj Pandey
  • Category: Market
No Comments
Fortis Healthcare vs Max Healthcare Institute 2027: The Market Pays 71x for One Hospital Chain and 57x for the Other
Fortis Healthcare vs Max Healthcare Institute at a glance Fortis Healthcare Max Healthcare Institute
Share price (16 Nov 2026) Rs 803.20 Rs 1,009.90
Market cap Rs 60,502 crore Rs 98,306 crore
P/E ratio 56.96 71.23
Q2 FY27 net profit Rs 320.5 crore Rs 414.4 crore

Quick Answer

Fortis Healthcare vs Max Healthcare Institute compares two of India’s largest listed hospital chains, both centred on north India. In Q2 FY27, Fortis grew revenue 16.5% to Rs 2,742 crore while net profit slipped 2.5% to Rs 321 crore. Max Healthcare grew revenue 20.4% to Rs 2,610 crore, but net profit fell 15.7% to Rs 414 crore against a high base. Max trades at a P/E of 71.23 and Fortis at 56.96.

Fortis Healthcare vs Max Healthcare Institute in 2027 is a question of how much investors will pay for hospital growth: Max Healthcare trades at 71.23 times earnings and Fortis at 56.96 times, even though both reported lower profit in the September 2026 quarter. The Fortis Healthcare vs Max Healthcare Institute valuation premium is built on margins and expansion plans.

Both companies run multi-speciality hospital networks with a strong base in Delhi NCR and other north Indian cities. Max Healthcare Institute is valued at about Rs 98,306 crore and Fortis Healthcare at about Rs 60,502 crore, and both belong to the broader Nifty 500. This Fortis Healthcare vs Max Healthcare Institute guide covers business models, valuation, Q2 FY27 results, 2027 drivers, risks and shareholding.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Fortis Healthcare vs Max Healthcare Institute: Company Overview
    • What Fortis Healthcare Does
    • What Max Healthcare Institute Does
  • How Fortis Healthcare and Max Healthcare Make Money
  • Fortis Healthcare vs Max Healthcare Institute Valuation
  • Fortis Healthcare vs Max Healthcare Institute Q2 FY27 Results
  • Fortis Healthcare vs Max Healthcare Valuation Drivers for 2027
    • Max Healthcare: new beds in premium markets
    • Fortis: network growth and diagnostics
    • Industry tailwinds
  • Risks in Fortis Healthcare vs Max Healthcare Institute
    • Risks for Fortis Healthcare
    • Risks for Max Healthcare Institute
  • Fortis Healthcare vs Max Healthcare Institute Shareholding
  • Which Investor Does Each Hospital Stock Suit?
    • Fortis Healthcare suits investors who want scale at a lower multiple
    • Max Healthcare Institute suits premium-growth investors
  • Final View on Fortis Healthcare vs Max Healthcare Institute
  • FAQs on Fortis Healthcare vs Max Healthcare Institute
    • Why did Max Healthcare's profit fall in Q2 FY27?
    • How did Fortis Healthcare perform in Q2 FY27?
    • Why does Max Healthcare trade at a higher P/E?
    • Who is the promoter of Fortis Healthcare?
    • Which hospital chain has higher FY26 revenue?
    • How far are both stocks from their 52-week highs?
    • Is Fortis Healthcare vs Max Healthcare Institute a buy or sell decision?

Fortis Healthcare vs Max Healthcare Institute: Company Overview

What Fortis Healthcare Does

Fortis Healthcare runs a network of multi-speciality and super-speciality hospitals across India, with a strong presence in Delhi NCR, Punjab, Maharashtra, Karnataka and West Bengal. It also owns a majority of Agilus Diagnostics, one of India’s large pathology chains.

Its promoter is Malaysia’s IHH Healthcare, which holds 31.17% of the company.

What Max Healthcare Institute Does

Max Healthcare Institute operates a chain of hospitals focused on high-end tertiary and quaternary care, mostly in Delhi NCR and north India. It also runs home care and pathology services linked to its hospitals.

Promoters hold 23.71%. The company is known for high revenue per occupied bed and one of the highest operating margins among listed hospital chains.

How Fortis Healthcare and Max Healthcare Make Money

Both companies earn revenue from inpatient treatment, surgeries, outpatient visits, diagnostics and pharmacy sales. The key measures are bed occupancy, average revenue per occupied bed and the mix of complex treatments such as cardiac, oncology and transplants.

Max focuses on high-value specialties and premium city locations, which supports its higher margin. Its operating margin was 29.3% in Q2 FY27 against 23.4% for Fortis.

Fortis has a wider network and a diagnostics business that adds scale but runs at lower margins than hospitals. In Fortis Healthcare vs Max Healthcare Institute, the margin difference is a large part of the valuation gap.

Fortis Healthcare vs Max Healthcare Institute Valuation

The Fortis Healthcare vs Max Healthcare Institute data uses the 16 November 2026 close and trailing twelve month ratios.

Fortis Healthcare vs Max Healthcare Institute metric Fortis Healthcare Max Healthcare Institute
Share price (CMP) Rs 803.20 Rs 1,009.90
52-week high Rs 1,010.10 Rs 1,185.40
52-week low Rs 704.95 Rs 797.00
Distance from 52-week high -20.5% -14.8%
Market capitalisation Rs 60,502 crore Rs 98,306 crore
P/E ratio (TTM) 56.96 71.23
Industry P/E 62.49 62.49
P/B ratio 5.77 8.68
Return on equity (ROE) 9.91% 12.18%
Debt to equity 0.30 0.33
Dividend yield 0.12% 0.20%
FY26 revenue Rs 9,178 crore Rs 8,536 crore
FY26 net profit Rs 1,064 crore Rs 1,442 crore

The Fortis Healthcare vs Max Healthcare Institute table shows Max trading at a P/E of 71.23 and 8.68 times book, against 56.96 and 5.77 for Fortis. The hospital industry P/E is 62.49, so Max trades above the sector and Fortis below it.

Max has the higher return on equity at 12.18% against 9.91% for Fortis. Both carry modest debt, with debt to equity of 0.33 for Max and 0.30 for Fortis.

Fortis’ share price of Rs 803.20 is about 20.5% below its 52-week high of Rs 1,010.10. Max at Rs 1,009.90 is about 14.8% below its high of Rs 1,185.40.

Fortis Healthcare vs Max Healthcare Institute Q2 FY27 Results

Figures below are consolidated revenue and net profit for the quarter ended 30 September 2026.

Fortis Healthcare vs Max Healthcare Institute Q2 FY27 (Sep 2026 quarter) Fortis Healthcare Max Healthcare Institute
Revenue Q2 FY27 Rs 2,742 crore Rs 2,610 crore
Revenue Q2 FY26 Rs 2,354 crore Rs 2,168 crore
Revenue change YoY +16.5% +20.4%
Net profit Q2 FY27 Rs 320.5 crore Rs 414.4 crore
Net profit Q2 FY26 Rs 328.8 crore Rs 491.3 crore
Net profit change YoY -2.5% -15.6%
Net profit Q1 FY27 Rs 272.8 crore Rs 323.0 crore

In the Q2 FY27 results, Fortis’ revenue rose 16.5% to Rs 2,742 crore, and net profit slipped 2.5% to Rs 320.5 crore. Its operating margin eased to 23.4% from 26.0%, though profit rose from Rs 272.8 crore in the June quarter.

Max Healthcare’s revenue rose 20.4% to Rs 2,610 crore and net profit fell 15.7% to Rs 414.4 crore. The year-ago figure of Rs 491.3 crore was well above its usual run-rate, and profit rose sharply from Rs 323 crore in Q1 FY27. Its operating margin improved to 29.3%.

For Fortis Healthcare vs Max Healthcare Institute, both chains grew revenue strongly. Max held and slightly improved its margin, while Fortis saw some margin pressure.

Fortis Healthcare vs Max Healthcare Valuation Drivers for 2027

Max Healthcare: new beds in premium markets

Max’s valuation premium rests on its plan to add beds in high-demand cities while keeping margins high. New hospitals usually take time to reach full occupancy, so expansion can weigh on margins before it adds to profit.

Its FY26 net profit rose about 34% to Rs 1,442 crore on revenue of Rs 8,536 crore.

Fortis: network growth and diagnostics

Fortis’ FY26 revenue rose about 17% to Rs 9,179 crore and net profit about 31% to Rs 1,064 crore. Its growth in 2027 depends on adding beds at existing hospitals, improving occupancy and growing its diagnostics arm.

In the Fortis Healthcare vs Max Healthcare Institute valuation debate, Fortis would need steady margin gains to move closer to Max’s multiple.

Industry tailwinds

Rising health insurance coverage, an ageing population and demand for complex treatments support all large hospital chains. Medical tourism into Delhi NCR also helps both companies. Regulatory caps on prices for some procedures remain a sector risk.

Compare hospital stocks on the Univest Screener

Risks in Fortis Healthcare vs Max Healthcare Institute

Risks for Fortis Healthcare

Fortis’ main risk is margin pressure as it adds capacity and runs a lower-margin diagnostics business. Its profit slipped in Q2 FY27 despite strong revenue growth. Foreign institutions cut their stake from 27.90% to 23.19%.

Risks for Max Healthcare Institute

In the Fortis Healthcare vs Max Healthcare Institute risk check, Max’s main risk is its high valuation. A P/E of 71.23 leaves little room for delays in new hospitals or margin dips. Foreign institutions cut their stake sharply from 51.80% to 40.52% over the year.

Fortis Healthcare vs Max Healthcare Institute Shareholding

Fortis Healthcare vs Max Healthcare Institute shareholding (Sep ’26, change vs Sep ’25) Fortis Healthcare Max Healthcare Institute
Promoters 31.17% (+0.00 pts) 23.71% (-0.03 pts)
Foreign institutions (FII) 23.19% (-4.71 pts) 40.52% (-11.28 pts)
Domestic institutions (DII) 34.46% (+5.32 pts) 31.00% (+10.97 pts)
Public and others 11.18% (-0.61 pts) 4.76% (+0.33 pts)

Fortis’ promoter IHH Healthcare holds 31.17%, unchanged over the year. Domestic institutions raised their stake from 29.14% to 34.46%.

Max promoters hold 23.71%. Domestic institutions raised their stake from 20.03% to 31.00%, while foreign institutions sold about 11 points. In Fortis Healthcare vs Max Healthcare Institute, domestic funds have become much larger holders of both stocks.

Download the Univest iOS App or Univest Android App to track Fortis and Max Healthcare live and follow daily healthcare research.

Which Investor Does Each Hospital Stock Suit?

Fortis Healthcare suits investors who want scale at a lower multiple

Within Fortis Healthcare vs Max Healthcare Institute, Fortis fits investors who want a large hospital network with a diagnostics arm, backed by a global promoter, at a P/E below the sector. They need to accept lower margins than Max.

Max Healthcare Institute suits premium-growth investors

Max fits investors who value high margins, a premium patient mix and expansion in strong markets. They need to accept a P/E above 70.

Final View on Fortis Healthcare vs Max Healthcare Institute

Fortis Healthcare vs Max Healthcare Institute shows how margins shape valuations in healthcare. Max earns a 29.3% operating margin and trades at 71.23 times earnings. Fortis earns 23.4% and trades at 56.96 times. Both grew revenue strongly in Q2 FY27 while profit slipped.

The Fortis Healthcare vs Max Healthcare Institute gap in 2027 will depend on how quickly new beds fill up and whether margins hold. Occupancy and revenue per bed are the numbers to watch.

Disclaimer: Data and figures in this article are drawn from publicly available information and company disclosures, and they may change after publication. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Fortis Healthcare vs Max Healthcare Institute

Why did Max Healthcare's profit fall in Q2 FY27?

Ans. Max Healthcare's net profit fell 15.7% to Rs 414.4 crore in Q2 FY27, against Rs 491.3 crore a year earlier. The year-ago figure was well above its usual quarterly level. Revenue rose 20.4% to Rs 2,610 crore, and profit grew sharply from Rs 323 crore in the June quarter. Its operating margin improved to 29.3%.

How did Fortis Healthcare perform in Q2 FY27?

Ans. Fortis' revenue rose 16.5% to Rs 2,742 crore, while net profit slipped 2.5% to Rs 320.5 crore in Q2 FY27. Its operating margin eased to 23.4% from 26.0%. Profit rose from Rs 272.8 crore in the June quarter. Its FY26 profit was Rs 1,064 crore.

Why does Max Healthcare trade at a higher P/E?

Ans. Max Healthcare trades at a P/E of 71.23 against 56.96 for Fortis. The market pays more for Max's higher operating margin and premium patient mix. Max also has a higher ROE of 12.18% against 9.91%. The hospital industry P/E is 62.49.

Who is the promoter of Fortis Healthcare?

Ans. Fortis Healthcare's promoter is Malaysia's IHH Healthcare, which holds 31.17%. Domestic institutions hold 34.46% and foreign institutions 23.19%. The public holds 11.18%. IHH is one of Asia's largest hospital operators.

Which hospital chain has higher FY26 revenue?

Ans. Fortis Healthcare reported FY26 revenue of Rs 9,179 crore against Rs 8,536 crore for Max Healthcare. Max had higher FY26 net profit at Rs 1,442 crore against Rs 1,064 crore for Fortis. Max's higher margin explains the gap. Both grew revenue by about 17% to 19%.

How far are both stocks from their 52-week highs?

Ans. Fortis closed at Rs 803.20 on 16 November 2026, about 20.5% below its 52-week high of Rs 1,010.10. Max closed at Rs 1,009.90, about 14.8% below its high of Rs 1,185.40. Fortis' 52-week low is Rs 704.95 and Max's is Rs 797. Prices change daily.

Is Fortis Healthcare vs Max Healthcare Institute a buy or sell decision?

Ans. This Fortis Healthcare vs Max Healthcare Institute comparison is educational and does not give a buy or sell call. Max offers higher margins at a P/E of 71.23, and Fortis offers a larger network at 56.96. Both depend on new capacity and occupancy. Investors should consult a SEBI-registered adviser before deciding.



2027 Fortis Healthcare hospitals Max Healthcare Institute Stock Comparison
Author: Neeraj Pandey
Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.

Leave a Reply Cancel reply